DK1888103T3 - Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering - Google Patents

Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering

Info

Publication number: DK1888103T3
Authority: DK; Denmark
Prior art keywords: exendin; glp; agonists; delay; prevent
Prior art date: 2005-04-11

Application number

DK06740942.5T

Other languages

English (en)

Inventor

Christen Anderson

Que Liu

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-11

Filing date

2006-04-11

Publication date

2012-04-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36926409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1888103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-04-11 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2012-04-23 Application granted granted Critical

2012-04-23 Publication of DK1888103T3 publication Critical patent/DK1888103T3/da

Links

238000007634 remodeling Methods 0.000 title abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
239000000556 agonist Substances 0.000 title abstract 2
230000000747 cardiac effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
230000003293 cardioprotective effect Effects 0.000 abstract 1
MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DK06740942.5T 2005-04-11 2006-04-11 Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering DK1888103T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66987605P	2005-04-11	2005-04-11
PCT/US2006/013949 WO2006110887A2 (en)	2005-04-11	2006-04-11	Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling

Publications (1)

Publication Number	Publication Date
DK1888103T3 true DK1888103T3 (da)	2012-04-23

Family

ID=36926409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06740942.5T DK1888103T3 (da)	2005-04-11	2006-04-11	Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering

Country Status (5)

Country	Link
US (1)	US8946149B2 (da)
EP (1)	EP1888103B1 (da)
AT (1)	ATE550032T1 (da)
DK (1)	DK1888103T3 (da)
WO (1)	WO2006110887A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2841097A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin and g-csf fusion proteins
CN102816241B (zh)	2004-02-09	2015-07-22	人类基因科学公司	清蛋白融合蛋白
MX2008015107A (es)	2006-05-26	2008-12-09	Amylin Pharmaceuticals Inc	Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
HUE031900T2 (en)	2008-12-10	2017-08-28	Glaxosmithkline Llc	Pharmaceutical compositions containing Albiglutide
EP2566502A4 (en)	2010-05-04	2013-10-09	Glaxosmithkline Llc	METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017066454A2 (en)	2015-10-14	2017-04-20	X-Therma, Inc.	Compositions and methods for reducing ice crystal formation
BR112021008180A2 (pt) *	2018-10-30	2021-08-03	Jianning Liu	polipeptídeo de glp-1 tendo atividade agonista de receptor glp-1 e uso do mesmo
TW202228762A (zh) *	2020-01-30	2022-08-01	美商美國禮來大藥廠	提派肽(tirzepatide)之治療用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554101A (en) *	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
ES2113879T3 (es)	1990-01-24	1998-05-16	Douglas I Buckley	Analogos de glp-1 utiles para el tratamiento de diabetes.
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
ES2293688T5 (es) *	1997-08-08	2011-05-04	Amylin Pharmaceuticals, Inc.	Nuevos compuestos análogos de la exendina.
NZ504258A (en)	1997-11-14	2002-12-20	Amylin Pharmaceuticals Inc	Exendin 3 and 4 agonist compounds for the treatment of diabetes
CA2309356C (en)	1997-11-14	2010-09-21	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
WO1999040788A1 (en)	1998-02-13	1999-08-19	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and glp-1
US6703359B1 (en) *	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
US6284725B1 (en) *	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
EP1292324A2 (en) *	2000-05-05	2003-03-19	Novo Nordisk A/S	Critical illness neuropathy
AU2001263230B2 (en) *	2000-05-19	2005-03-10	Amylin Pharmaceuticals, Llc	Treatment of acute coronary syndrome with glp-1
CA2395165C (en) *	2000-10-20	2012-05-22	Mario Ehlers	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
AU2002239384B2 (en) *	2000-12-13	2007-01-11	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002322403A1 (en) *	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
US20030199445A1 (en) *	2002-02-07	2003-10-23	Knudsen Lotte Bjerre	Use of GLP-1 compound for treatment of critically ill patients
EP1494704A1 (en)	2002-04-04	2005-01-12	Novo Nordisk A/S	Glp-1 agonist and cardiovascular complications
AU2003282955A1 (en) *	2002-10-17	2004-05-04	Alkermes Controlled Therapeutics, Inc. Ii	Microencapsulation and sustained release of biologically active polypeptides
US7192922B2 (en) *	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
US7186692B2 (en) *	2002-12-17	2007-03-06	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7790681B2 (en) *	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1610811A4 (en)	2002-12-17	2008-03-26	Amylin Pharmaceuticals Inc	PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
US8008255B2 (en)	2003-05-30	2011-08-30	Amylin Pharmaceuticals, Inc.	Methods and compositions for enhanced transmucosal delivery of peptides and proteins
JP2007500243A (ja) *	2003-06-09	2007-01-11	ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド	成長ホルモンの増進された経粘膜送達のための組成物および方法
EP1701731A4 (en) *	2003-12-12	2009-08-05	Einstein Coll Med	GLP-1 (9-36) METHOD AND COMPOSITIONS
EP1838336A2 (en) *	2004-12-24	2007-10-03	Amylin Pharmaceuticals, Inc.	Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
MX2008015107A (es) *	2006-05-26	2008-12-09	Amylin Pharmaceuticals Inc	Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.

2006
- 2006-04-11 DK DK06740942.5T patent/DK1888103T3/da active
- 2006-04-11 EP EP06740942A patent/EP1888103B1/en not_active Expired - Lifetime
- 2006-04-11 US US11/910,730 patent/US8946149B2/en active Active
- 2006-04-11 AT AT06740942T patent/ATE550032T1/de active
- 2006-04-11 WO PCT/US2006/013949 patent/WO2006110887A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2006110887A3 (en)	2007-03-22
US20090137466A1 (en)	2009-05-28
EP1888103B1 (en)	2012-03-21
US8946149B2 (en)	2015-02-03
ATE550032T1 (de)	2012-04-15
WO2006110887A2 (en)	2006-10-19
EP1888103A2 (en)	2008-02-20

Publication	Publication Date	Title
ATE550032T1 (de)	2012-04-15	Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung
DK2358717T3 (da)	2013-11-18	Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
SA521431209B1 (ar)	2024-08-05	مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
JOP20220024A1 (ar)	2023-01-30	مركبات مساعدة لـ gipr
NO331089B1 (no)	2011-10-03	Sammensetning omfattende en GPR119-agonist og en DPP-IV-inhibitor samt fremgangsmate for fremstilling av slike.
DK4209490T3 (da)	2026-02-23	2-(((2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1h-benzo[d]imidazol-6-carboxylsyrederivater og lignende forbindelser som glp-1-modulatorer til behandling af diabetes
NO20084278L (no)	2008-10-30	Bezothiazol derivatives as beta2 adrenoreceptor agonists
NO20070487L (no)	2007-03-05	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
WO2008019147A3 (en)	2009-06-11	Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
EA201791281A1 (ru)	2017-11-30	Соединения-коагонисты гип и гпп-1
NZ740644A (en)	2019-10-25	Glucagon receptor agonists
DK2565191T3 (da)	2014-11-10	4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati
DK1523325T3 (da)	2011-11-21	Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom
EP3765086C0 (en)	2025-01-08	COMPOSITION AFFECTING THE CONCENTRATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) TO ATTENUATE THE EFFECTS OF AGING
PE20121088A1 (es)	2012-08-17	Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
WO2004056313A3 (en)	2004-11-25	Prevention and treatment of cardiac arrhythmias
WO2008155900A1 (ja)	2008-12-24	糖鎖付加glp-1ペプチド
EP3922260A3 (en)	2022-06-15	Insulin receptor partial agonists and glp-1 analogues
NO20075082L (no)	2007-10-31	Pyridin-3-karboksamidderivater som CB1-inversagonister
CO6410287A2 (es)	2012-03-30	Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma
DK2203430T3 (da)	2011-09-26	N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
NO20084645L (no)	2008-12-19	Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
NO20084637L (no)	2008-12-15	Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
EA201101187A1 (ru)	2012-10-30	Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
EA201270555A1 (ru)	2012-09-28	Комбинации ингибиторов вируса гепатита с